Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512338 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Aleksandar Kuzmanov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Urologic Oncology and Stem Cell Therapy, Department of Urology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzer…. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Niedermaier Stiftung.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA)-based imaging improved the detection of primary, recurrent and metastatic prostate cancer. However, in certain patients, a low PSMA surface expression can be a limitation for this promising diagnostic tool. Pharmacological induction of PSMA might be useful to further improve the detection rate of PSMA-based imaging. To achieve this, we tested dutasteride (Duta)—generally used for treatment of benign prostatic enlargement—and lovastatin (Lova)—a compound used to reduce blood lipid concentrations. We aimed to compare the individual effects of Duta and Lova on cell proliferation as well as PSMA expression. In addition, we tested if a combination treatment using lower concentrations of Duta and Lova can further induce PSMA expression. Our results show that a treatment with ≤1 μM Duta and ≥1 μM Lova lead to a significant upregulation of whole and cell surface PSMA expression in LNCaP, C4-2 and VCaP cells. Lower concentrations of Duta and Lova in combination (0.5 μM Duta + 0.5 μM Lova or 0.5 μM Duta + 1 μM Lova) were further capable of enhancing PSMA protein expression compared to a single compound treatment using higher concentrations in all tested cell lines (LNCaP, C4-2 and VCaP).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Urologic Oncology and Stem Cell Therapy, Department of Urology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland.
- Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
- Department of Nuclear Medicine, Baden Cantonal Hospital, 5404 Baden, Switzerland.
ORCID-Profile: Souzan Salemi, Florian A Schmid, Irene A Burger, Daniel Eberli, Benedikt Kranzbühler
Förderung
- Niedermaier Stiftung
Zitieren
APA
Kuzmanov, A., Salemi, S., Schmid, F. A., Burger, I. A., Eberli, D., & Kranzbühler, B. (2023). Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512338
Vancouver
Kuzmanov A, Salemi S, Schmid FA, Burger IA, Eberli D, Kranzbühler B. Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512338
BibTeX
@article{Kuzmanov2023,
author = {Kuzmanov, Aleksandar and Salemi, Souzan and Schmid, Florian A and Burger, Irene A and Eberli, Daniel and Kranzbühler, Benedikt},
title = {Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512338}
}
EUVIMED